Adage Capital Management
Adage Capital is a Boston-based hedge fund founded by Phillip Gross which held nearly $24 billion in securities at the end of the quarter ended September 30, 2010.
The firm focuses on managing S&P 500 assets predominantly for Endowments and Foundations such as Harvard University, Northwestern University, Dartmouth College, the American Red Cross and the Getty Foundation.
The firm focuses on managing S&P 500 assets predominantly for Endowments and Foundations such as Harvard University, Northwestern University, Dartmouth College, the American Red Cross and the Getty Foundation.
View Older Stories View More Recent Stories
-
Form SCHEDULE 13G/A Solid Biosciences Inc. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A EyePoint, Inc. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A ABEONA THERAPEUTICS INC. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Crane Harbor Acquisition Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A MONRO, INC. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Wave Life Sciences Ltd. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G NABORS INDUSTRIES LTD Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Launchpad Cadenza Acquis Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Metropolitan Bank Holdin Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Leapfrog Acquisition Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Karyopharm Therapeutics Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Viking Acquisition Corp Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Karbon Capital Partners Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Evolution Global Acquisi Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Minerva Neurosciences, Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Tailwind 2.0 Acquisition Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Hall Chadwick Acquisitio Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Insight Digital Partners Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Dynamix Corp III Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Pasithea Therapeutics Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G American Drive Acquisiti Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Bain Capital GSS Investm Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G General Purpose Acquisit Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Apex Treasury Corp Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Lifezone Metals Ltd Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Activate Energy Acquisit Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Invest Green Acquisition Filed by: Adage Capital Management, L.P.
-
Form D/A Adage Capital Partners,
-
CORXEL Announces $287 million Series D1 Financing to Further Advance Its Cardiometabolic Pipeline including Oral Small Molecule GLP-1 Receptor Agonist
-
Mirador Accelerates Multi-Asset Clinical Pipeline in Immuno-Fibrotic Disease; Closes $250 Million Series B with Premier Investors
-
Immunic Highlights 2025 Accomplishments and Upcoming Milestones
-
Ambros Therapeutics Launches with $125 Million Series A Financing to Advance Neridronate Through Phase 3 Registrational Program for Complex Regional Pain Syndrome Type 1
-
Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock
-
Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock
-
Pathway to Cures Invests in SeraGene Therapeutics
-
Form 13F-NT Adage Capital Management For: Sep 30
-
Form 13F-HR ADAGE CAPITAL PARTNERS For: Sep 30
-
Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update
-
Form SCHEDULE 13G iBio, Inc. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G INOVIO PHARMACEUTICALS, Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Sitio Royalties Corp. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Dynamix Corp Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A ABEONA THERAPEUTICS INC. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Equillium, Inc. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Milestone Pharmaceutical Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A SOLENO THERAPEUTICS INC Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Solid Biosciences Inc. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A EyePoint Pharmaceuticals Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Traws Pharma, Inc. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Aclaris Therapeutics, Filed by: Adage Capital Management, L.P.

